

## LETTER

doi:10.1038/s41586-019-1027-4

**HIV-1 remission following CCR5 $\Delta$ 32/ $\Delta$ 32 haematopoietic stem-cell transplantation**

Ravindra K Gupta, Sultan Abdul-jawad, Laura E McCoy, Hoi Ping Mok, Dimitra Peppas, Maria Salgado, Javier Martinez-Picado, Monique Nijhuis, Annemarie M.J. Wensing, Helen Lee, Paul Grant, Eleni Nastouli, Jonathan Lambert, Matthew Pace, Fanny Salasc, Christopher Monit, Andrew Innes, Luke Muir, Laura Waters, John Frater, Andrew ML Lever, SG Edwards, Ian H Gabriel & Eduardo Olavarria

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. *Nature* is providing this early version of the typeset paper as a service to our customers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Cite this article as: Gupta, R. et al. HIV-1 remission following CCR5 $\Delta$ 32/ $\Delta$ 32 haematopoietic stem-cell transplantation. *Nature* <https://doi.org/10.1038/s41586-019-1027-4> (2019).

Received: 7 February 2019; Accepted: 26 February 2019;  
Accelerated Article Preview Published online 5 March 2019.

# HIV-1 remission following CCR5 $\Delta$ 32/ $\Delta$ 32 haematopoietic stem-cell transplantation

Ravindra K Gupta<sup>1,2,3,4\*</sup>, Sultan Abdul-jawad<sup>1</sup>, Laura E McCoy<sup>1</sup>, Hoi Ping Mok<sup>4</sup>, Dimitra Peppas<sup>3,5</sup>, Maria Salgado<sup>6</sup>, Javier Martinez-Picado<sup>6,7,8</sup>, Monique Nijhuis<sup>9</sup>, Annemarie M. J. Wensing<sup>9</sup>, Helen Lee<sup>10</sup>, Paul Grant<sup>11</sup>, Eleni Nastouli<sup>1,11</sup>, Jonathan Lambert<sup>12</sup>, Matthew Pace<sup>5</sup>, Fanny Salasc<sup>4</sup>, Christopher Monit<sup>1</sup>, Andrew Innes<sup>13,14</sup>, Luke Muir<sup>1</sup>, Laura Waters<sup>3</sup>, John Frater<sup>5,15</sup>, Andrew ML Lever<sup>4,16</sup>, SG Edwards<sup>3</sup>, Ian H Gabriel<sup>13,14,17,18</sup> & Eduardo Olavarria<sup>13,14,18</sup>

**HIV-1 cure remains elusive with only one reported case a decade ago<sup>1,2</sup>. Termed the ‘Berlin patient’, the individual underwent two allogeneic haematopoietic stem-cell transplantation (allo-HSCT) procedures using a donor with a homozygous mutation in the HIV coreceptor CCR5 (CCR5 $\Delta$ 32/ $\Delta$ 32) to treat his acute myeloid leukaemia. Total body irradiation was given with each HSCT. Critically, it is unclear which treatment or patient parameters contributed to this only documented case of long-term HIV remission. Here we show that HIV-1 remission may be possible with a less aggressive and toxic approach. An HIV-1-infected adult underwent allo-HSCT for Hodgkin’s lymphoma using cells from a CCR5 $\Delta$ 32/ $\Delta$ 32 donor. He experienced mild gut graft versus host disease. Antiretroviral therapy was interrupted 16 months after transplantation. HIV-1 remission has been maintained through a further 18 months. Plasma HIV-1 RNA has been undetectable at less than 1 copy per millilitre along with undetectable HIV-1 DNA in peripheral CD4 T lymphocytes. Quantitative viral outgrowth assay from peripheral CD4 T lymphocytes shows no reactivatable virus using a total of 24 million resting CD4 T cells. CCR5-tropic, but not CXCR4-tropic viruses were identified in HIV-1 DNA from CD4 T cells of the patient prior to transplant. CD4 T cells isolated from peripheral blood post-transplant did not express CCR5 and were only susceptible to CXCR4-tropic virus *ex vivo*. HIV-1 Gag-specific CD4 and CD8 T cell responses were lost after transplantation, whereas cytomegalovirus (CMV)-specific responses were detectable. Likewise, HIV-1-specific antibodies and avidities fell to levels comparable to those in the Berlin patient following transplantation. Although at 18 months post-treatment interruption it is premature to conclude that this patient has been cured, these data suggest that single allo-HSCT with homozygous CCR5 $\Delta$ 32 donor cells may be sufficient to achieve HIV-1 remission with reduced intensity conditioning and no irradiation, and the findings further support the development of HIV remission strategies based on preventing CCR5 expression.**

The HIV-1 epidemic continues with nearly 37 million infected.<sup>3</sup> Although over 21 million are accessing lifelong antiretroviral therapy (ART)<sup>3</sup>, drug resistant HIV in both untreated<sup>4</sup> and treated<sup>5,6</sup> individuals is significant in low and middle-income countries and sustainability of ART programs is uncertain.<sup>7</sup> Drug-free durable HIV-1 suppression is therefore an urgent global priority.

Thus far, the only documented case of sustained HIV remission is the ‘Berlin Patient’, who received two allogeneic hematopoietic stem cell transplantations (allo-HSCT) using cells from a homozygous CCR5 $\Delta$ 32 (CCR5 $\Delta$ 32/ $\Delta$ 32) donor<sup>1</sup>. This 32-base pair deletion

prevents CCR5 expression rendering these cells resistant to infection with HIV variants utilising the CCR5 co-receptor<sup>8</sup>.

The only other case of an HIV-infected patient transplanted with CCR5 $\Delta$ 32/ $\Delta$ 32 cells who interrupted ART was the ‘Essen Patient’<sup>9</sup>. In this case in which ART was interrupted one week before allo-HSCT, a rapid viral rebound of a pre-existing minority HIV-1 variant able to infect cells via the alternative CXCR4 co-receptor was observed three weeks later<sup>9,10</sup>. Such pre-existing CXCR4 variants were not observed in the ‘Berlin patient’<sup>11</sup>. Three other cases transplanted with wildtype CCR5 cells experienced a viral rebound 12, 32 or 41 weeks after ART interruption despite profound reduction of the HIV reservoir.<sup>12,13</sup>

We report an individual diagnosed with HIV infection in 2003, with a CD4 nadir of 290 cells/mm<sup>3</sup> and baseline HIV-1 plasma viral load (pVL) of 180,000 copies/ml. ART was initiated with tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and efavirenz (EFV) in 2012.

In December 2012 Stage IVB (nodular sclerosing) Hodgkin’s Lymphoma (HL) was diagnosed. HL was refractory to first-line chemotherapy (ABVD) and a number of salvage regimens including ESHAP, anti-CD30 monoclonal antibody (Brentuximab) and mini-LEAM were used. ART was switched to TDF/FTC/raltegravir (RAL) during periods of chemotherapy for HL; there was a 5-day episode of ART interruption in late 2015 with HIV-1 pVL of 1,500 copies/ml that did not reach viral set-point. Based on resistance mutations K65R and M184V in *reverse transcriptase* as well as E157Q in *integrase*, the regimen was switched to rilpivirine (RPV), lamivudine (3TC) and dolutegravir (DTG), with viral suppression subsequently achieved.

Mobilisation of autologous peripheral blood stem cells failed despite the use of CXCR4 antagonists, thereby precluding standard autologous HSCT. A complete metabolic remission by CT/PET criteria was achieved with IGEV chemotherapy in March 2016.

An unrelated (9/10) donor was identified from an international registry with one allelic mismatch at HLA-B by high-resolution HLA typing that also was CCR5 $\Delta$ 32/ $\Delta$ 32 (*Extended data table 1 and methods*). No fully matched donors were identified in the registry. The patient underwent conditioning with Lomustine, Cyclophosphamide, Ara-C and Etoposide (LACE) followed by infusion of  $3.6 \times 10^6$  CD34<sup>+</sup> cells/kg. *In vivo* T-cell depletion employed anti-CD52 (Alemtuzumab), 10 mg daily for 5 days (days -7 to -3) and GvHD prophylaxis used Cyclosporine-A (CsA) with a short-course of methotrexate (MTX). ART was continued throughout with RPV/3TC/DTG (*Figure 1a*). Allo-HSCT was relatively uncomplicated and the patient was discharged on Day+31. Both Epstein-Barr Virus (EBV) and cytomegalovirus (CMV) reactivation occurred at day +85 requiring treatment with anti-CD20

<sup>1</sup>Division of Infection and Immunity, UCL, London, UK. <sup>2</sup>Department of Infection, UCLH, London, UK. <sup>3</sup>Mortimer Market Centre, Dep of HIV, CNWL NHS Trust, London, UK. <sup>4</sup>Department of Medicine, University of Cambridge, Cambridge, UK. <sup>5</sup>Nuffield Department of Medicine, University of Oxford, Oxford, UK. <sup>6</sup>IrsiCaixa AIDS Research Institute, Badalona, Spain. <sup>7</sup>University of Vic – Central University of Catalonia (UVic-UCC), Vic, Spain. <sup>8</sup>Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. <sup>9</sup>Translational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands. <sup>10</sup>Department of Haematology, University of Cambridge, Cambridge, UK. <sup>11</sup>Department of Virology, UCLH, London, UK. <sup>12</sup>Department of Haematology, UCLH, London, UK. <sup>13</sup>Department of Clinical Haematology, Imperial College NHS Healthcare Trust, Hammersmith Hospital, London, UK. <sup>14</sup>Imperial College London, London, UK. <sup>15</sup>NIHR Oxford Biomedical Research Centre, Oxford, UK. <sup>16</sup>Department of Medicine, National University of Singapore, Singapore. <sup>17</sup>Department of Haematology, Chelsea and Westminster Hospitals Foundation NHS Trust, London, UK. <sup>18</sup>These authors contributed equally: Ian H Gabriel, Eduardo Olavarria. \*e-mail: rkg20@cam.ac.uk

monoclonal antibody (Rituximab) and ganciclovir respectively. At day +77 the patient presented with fever and gastrointestinal symptoms. Gastric, duodenal and colonic biopsies were consistent with grade 1 GvHD, which resolved without intervention. Full-donor chimerism was achieved in the whole leukocyte and in CD3+ T cell fractions from day +30 and maintained in both cell fractions throughout (Figure 1b). Host genotype was CCR5wt/wt before allo-HSCT, and became CCR5 $\Delta$ 32/ $\Delta$ 32 after transplant (Figure 1c), with loss of CCR5 surface expression from circulating CD4 and CD8 T cells (Figure 1d). At +180 days post-transplant CsA was discontinued. CT/PET scan at +120 days and +365 days post-transplant confirmed complete metabolic remission with no subsequent relapse. Post-transplant white cell counts and lymphocyte subsets returned to pre-transplant levels (extended data figure 1), except for CD4 counts which have been slower to recover (Figure 1a).

ART was maintained post-HSCT and analytical treatment interruption (ATI) was initiated at day +510 (September 2017). Weekly plasma viral load was performed for the first 3 months and then monthly thereafter. HIV-1 pVL remained undetectable thereafter with limit of detection (LOD) <1 copy RNA/ml (Figure 1a). Plasma concentrations of TDF, 3TC and DTG were negative by HPLC at day +648 and a panel of all currently available antiretroviral drugs tested negative by LC-MS at +973 days. Total PBMC associated HIV-1 DNA fell to below the limit of detection after transplant (Figure 1b). Total DNA in CD4+ T cells at day +876 was undetectable in all replicates by ultra-sensitive qPCR (<0.65 HIV LTR copies/million cells and <0.69 HIV-1 Gag copies/million cells) and in 7/8 replicates of the ultra-sensitive HIV-1 LTR ddPCR<sup>14</sup>; in one replicate a low-level signal was observed. Such occasional positive signals were also observed in the Berlin patient<sup>15</sup> and may reflect a false ddPCR signal, potential contamination, or evidence of very low levels of persistence of HIV infected cells that either did not harbor fully replication competent virus or were unable to lead to recrudescence given that the vast majority of target cells are incapable of being infected with this patient's HIV CCR5 tropic variants (Figure 2). HIV-1 DNA and RNA were also repeatedly undetectable in whole blood when tested with SAMBA II, a CE marked point-of-care isothermal amplification method (LOD: 284 copies/ml; 95% CI: 214–378 copies/ml)<sup>16</sup>.

Blood was obtained for a modified Quantitative Viral Outgrowth Assay (QVOA)<sup>17,18</sup> at three time points post-HSCT at day +217 (on ART), and days +678 and +876 (off ART). QVOA was undetectable on all occasions, giving a reservoir estimation in infectious units per million (IUPM) resting CD4 T cells of <0.286, <0.309 and <0.063 respectively. Pooling the results from the three qVOA tests on a total of 24 million resting CD4 T cells gives an estimate of <0.029 IUPM.

We next sought to confirm that the post-transplant CD4 cells lacked expression of CCR5 and were resistant to HIV-1 infection (Figure 2 and Extended data Figure 2). These CD4 T cells from the study patient were challenged *in vitro* with the CCR5-tropic viruses Ba-L and ZM247 and productive HIV-1 infection over 7 days was measured by (i) intracellular staining for HIV-1 p24 protein (Figure 2a-b) and (ii) infectivity of culture supernatants on indicator cell lines that respond to expression of HIV Tat protein (Extended data Figure 2). In contrast to a HIV-negative donor, post-transplant cells from the study patient could not be infected with either CCR5 tropic virus (Figure 2a-b). The study patient cells were then challenged with the canonical CXCR4-tropic HIV-1<sub>NI4.3</sub>. As expected, infection was observed in cells and supernatants from both the patient and an HIV-negative donor (control) (Figure 2a-b and extended data Figure 2).

In order to determine whether the study patient was infected with CCR5- or CXCR4-using virus (or both), we deep-sequenced the V3 loop in HIV-1 envelope (the key determinant of coreceptor usage) and computational algorithms predicted CCR5-tropism<sup>19,20</sup>. For phenotypic verification we first performed single genome sequencing (SGS) of gp120 from pre-transplant PBMC by limiting dilution PCR<sup>21,22</sup>. (Figure 2c). These single genomes were cloned into expression vectors and used to generate virions pseudotyped with patient derived

gp120 envelope protein (Figure 2d)<sup>21</sup>, before infection of indicator cells expressing either CCR5 or CXCR4. As predicted from the genotype, robust infection was observed in CCR5 but not CXCR4 expressing cells (Figure 2d).

Analyses of both antibody and T cell responses were undertaken in order to further investigate absence of persistent HIV-1 infection and antigenic stimulation. Western blot analysis of antibodies demonstrated loss of p24, p31 and multiple other bands between pre- and post-transplant time points in a similar pattern seen previously in other transplanted patients who have remained on ART<sup>23</sup> (Figure 3a and Extended Data table 2), whilst antibodies to envelope protein gp160 and standard ELISA for Env antibodies persisted (Figure 3a-c). Low-sensitivity VITROS analysis and antibody avidity assays were also consistent with loss of HIV antigen following allo-HSCT (Figure 3d-e)<sup>15</sup>. CD8 and CD4 T cell virus-specific responses were determined following stimulation with HIV-1 Gag and CMV pp65 overlapping peptide pools (Figure 4a). Small Gag-virus specific T-cell responses were identified by intracellular staining and multifunctional responses (IFN- $\gamma$ , CD107a, TNF- $\alpha$  and IL-2) were detected prior to HSCT (day -35) but not at days +72, 96, 510 and 819 after the procedure (Figure 4a-b). No HIV-1 specific T cell responses were detected to Nef, Pol and Env peptide pools at days +96 and +819 post-transplant (Extended data Figure 3). By contrast CMV-specific T-cell responses were detected both before and after HSCT, albeit at reduced frequencies (Figure 4a-c).

Both antibody and T cell responses observed here are highly reminiscent of observations in the Berlin patient.<sup>1,15</sup> Important similarities between the two cases were CCR5-tropic HIV-1 infection and receipt of a CCR5 $\Delta$ 32/ $\Delta$ 32 transplant. The GvHD prophylaxis was very similar and utilized standard regimens (CsA + MMF *versus* CsA + MTX) that in randomized studies have shown similar outcomes.<sup>24</sup> In both cases there was probable mild GvHD, which may have contributed to the loss of HIV-infected cells. Finally, both achieved and maintained full-donor chimerism in peripheral blood that might have contributed to reduced reservoir size<sup>23,25</sup>.

Notable differences were that before allo-HSCT our patient was homozygous CCR5 wildtype as compared to the heterozygous CCR5WT/ $\Delta$ 32 genotype observed in the ‘Berlin Patient’. Our patient received a reduced intensity conditioning regimen consisting exclusively of chemotherapy agents with known activity against lymphoma<sup>26</sup> while the Berlin patient received total body irradiation in conjunction with cyclophosphamide as the conditioning regimen. For lymphodepletion our patient received anti-CD52 Campath while the Berlin patient was treated with antithymocyte globulin. Our patient was treated with a short course of anti CD20 for EBV reactivation. There has been recent interest in the potential for anti-B cell therapy to disrupt B cell follicles that are known to harbour persistent HIV in lymphoid tissues<sup>27</sup>, though we think this mechanism is unlikely to be related to remission observed here. Finally, this patient achieved full remission after a single allo-HSCT while the Berlin patient experienced a relapse of the AML and received further chemotherapy with an anti-CD33 monoclonal conjugate before a second allo-HSCT.

In terms of a road map forward we speculate that CCR5 gene therapy strategies using stem cells could conceivably be a scalable approach to remission. As significant graft-versus-host effect is likely important, manifesting as early and sustained full donor chimerism in T cells, an autologous approach needs to achieve high levels of replacement by CCR5 depleted cells. Depletion of the CD4+ CCR5+ T cells other potential HIV reservoirs is a major challenge given the toxicities associated with anti-thymocyte globulin and anti-CD52 and the unknown role of anti-proliferative agents such as cyclosporin or methotrexate in clearing infected cells.

This report demonstrates (i) that the ‘Berlin’ patient was not an anomaly; (ii) that remission of HIV infection can be achieved with reduced intensity drug regimens (iii) that a single CCR5 $\Delta$ 32/ $\Delta$ 32 allo-HSCT is sufficient and (iv) that total body irradiation is not required. Our observation supports the development of HIV cure strategies based on preventing the expression of the CCR5 coreceptor.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at <https://doi.org/10.1038/s41586-019-1027-4>.

Received: 7 February 2019; Accepted: 26 February 2019;

Published online 5 March 2019.

- Hutter, G. *et al.* Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med* **360**, 692–698, doi.org/10.1056/NEJMoa0802905 (2009).
- Allers, K. *et al.* Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. *Blood* **117**, 2791–2799, doi.org/10.1182/blood-2010-09-309591 (2011).
- UNAIDS. *UNAIDS DATA*, <[http://www.unaids.org/en/resources/documents/2017/20170720\\_Data\\_book\\_2017](http://www.unaids.org/en/resources/documents/2017/20170720_Data_book_2017)> (2017).
- Gupta, R. K. *et al.* HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *Lancet Infect Dis* **18**, 346–355, doi.org/10.1016/S1473-3099(17)30702-8 (2018).
- TenoRes Study, G. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. *Lancet Infect Dis* **16**, 565–575, doi.org/10.1016/S1473-3099(15)00536-8 (2016).
- Barth, R. E., van der Loeff, M. F., Schuurman, R., Hoepelman, A. I. & Wensing, A. M. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. *Lancet Infect Dis* **10**, 155–166 (2010).
- Avert. *FUNDING FOR HIV AND AIDS*, <<https://www.avert.org/professionals/hiv-around-world/global-response/funding>> (2017).
- Simmons, G. *et al.* Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. *Journal of virology* **70**, 8355–8360 (1996).
- Kordelas, L. *et al.* Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. *N Engl J Med* **371**, 880–882, doi.org/10.1056/NEJMc1405805 (2014).
- Verheyen, J. *et al.* Rapid rebound of a preexisting CXCR4-tropic HIV variant after allogeneic transplantation with CCR5 delta32 homozygous stem cells. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, doi.org/10.1093/cid/ciy565 (2018).
- Symons, J. *et al.* Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **59**, 596–600, doi.org/10.1093/cid/ciu284 (2014).
- Henrich, T. J. *et al.* Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. *Ann Intern Med* **161**, 319–327, doi.org/10.7326/M14-1027 (2014).
- Cummins, N. W. *et al.* Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. *PLoS medicine* **14**, e1002461, doi.org/10.1371/journal.pmed.1002461 (2017).
- Bosman, K. J. *et al.* Development of sensitive ddPCR assays to reliably quantify the proviral DNA reservoir in all common circulating HIV subtypes and recombinant forms. *J Int AIDS Soc* **21**, e25185, doi.org/10.1002/jia2.25185 (2018).
- Yuki, S. A. *et al.* Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. *PLoS pathogens* **9**, e1003347, doi.org/10.1371/journal.ppat.1003347 (2013).
- Ritchie, A. V. *et al.* Performance evaluation of the point-of-care SAMBA I and II HIV-1 Qual whole blood tests. *J Virol Methods* **237**, 143–149, doi.org/10.1016/j.jviromet.2016.08.017 (2016).
- Laird, G. M. *et al.* Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. *PLoS pathogens* **9**, e1003398, doi.org/10.1371/journal.ppat.1003398 (2013).
- Fun, A., Mok, H. P., Wills, M. R. & Lever, A. M. A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir. *Sci Rep* **7**, 43231, doi.org/10.1038/srep43231 (2017).
- Jensen, M. A., Coetzer, M., van 't Wout, A. B., Morris, L. & Mullins, J. I. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. *Journal of virology* **80**, 4698–4704, doi.org/10.1128/JVI.80.10.4698-4704.2006 (2006).
- Lengauer, T., Sander, O., Sierra, S., Thielen, A. & Kaiser, R. Bioinformatics prediction of HIV coreceptor usage. *Nature biotechnology* **25**, 1407–1410, doi.org/10.1038/nbt1371 (2007).
- Smith, N. M. *et al.* Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, doi.org/10.1093/cid/civ219 (2015).
- Watters, S. A. *et al.* Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control. *PLoS one* **11**, e0158854, doi.org/10.1371/journal.pone.0158854 (2016).
- Salgado, M. *et al.* Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. *Ann Intern Med* **169**, 674–683, doi.org/10.7326/M18-0759 (2018).
- Hamilton, B. K. *et al.* Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation. *Bone Marrow Transplant* **48**, 1578–1580, doi.org/10.1038/bmt.2013.89 (2013).
- Duarte, R. F. *et al.* CCR5 Delta32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. *Lancet HIV* **2**, e236–242, doi.org/10.1016/S2352-3018(15)00083-1 (2015).
- Pavlu, J. *et al.* LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. *Hematol Oncol* **29**, 75–80, doi.org/10.1002/hon.956 (2011).
- Bronnimann, M. P., Skinner, P. J. & Connick, E. The B-Cell Follicle in HIV Infection: Barrier to a Cure. *Front Immunol* **9**, 20, doi.org/10.3389/fimmu.2018.00020 (2018).

**Acknowledgements** This study was funded by a Wellcome Trust Senior Fellowship in Clinical Science to RKG, research capability funding (RCF) from UCLH BRC to RKG, as well as funding from Oxford and Cambridge Biomedical Research Centres (BRC), amfAR (The Foundation for AIDS Research), through the amfAR Research Consortium on HIV Eradication (ARCHE) program (AmfAR 109858-64-RSRL), the MRC (MR/R008698/1 to LEM and MRM008614/2 to DP). AJI is supported by an NIHR Clinical Lectureship, and acknowledges support from the NIHR and Imperial Biomedical Research Centre (BRC). We would like to thank the CHERUB (<http://www.cherub.uk.net>) and IciStem Consortia ([www.icistem.org](http://www.icistem.org)) for support and continuous discussion of results. We would also like to thank Nina Parmahand, Mikaila Bandara, Isobel Jarvis, Axel Fun, Kirit Ardeschna, Alison Hill, Neha Goel, Richard Szydlo, David Slade, Sarah Griffith and Cristina Gálvez. Águeda Hernández Rodríguez, Victoria González Soler and Belén Rivaya Sánchez from the Microbiology Department of the Hospital Germans Trias i Pujol, Erik van Maarseveen from the department of Pharmacology, and Laura Huyveneers, Pauline Schipper and Dorien de Jong from the Translational Virology Group of the department of Medical Microbiology of the UMC Utrecht. Finally, we would also like to thank Professor Jane Apperley, Zoe Allwood and Sandra Loaiza from Imperial College Healthcare NHS Trust and all the nurses in the BMT Unit that looked after the patient.

**Reviewer information** Nature thanks Steven Deeks, Timothy Henrich and the other anonymous reviewer(s) for their contribution to the peer review of this work.

**Author contributions** Conception and design: RKG, SAJ, SGE, EO, HPM and IHG. Designed and/or performed experiments: SAJ, JMP, AMW, MS, MN, FS, SA, LEM, IHG, LMc, DP, HPM, PG, EN, AL, LW, SGE, MP, EN, PG, CM. Analysis and interpreted data: RKG, JMP, AMW, SAJ, MS, MN, FS, SA, LEM, LMc, EO, HL, JF, MP, IHG, HPM, SGE, EN, PG, JL, AJ, CM. Drafting of the article: RKG, MN, AMW, JMP, AL, JL, HPM, JL, AJ. Critical revision of the article for important intellectual content: JMP, AMW, MS, MN, FS, SA, LEM, LMc, DP, HPM, PG, EN, AL, SGE, LW, MP, IHG, HPM, AJ.

**Competing interests** The authors declare no competing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41586-019-1027-4>.

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41586-019-1027-4>.


**Reprints and permissions information** is available at <http://www.nature.com/reprints>.

**Correspondence and requests for materials** should be addressed to R.K.G. **Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


© The Author(s), under exclusive licence to Springer Nature Limited 2019



**Fig. 1 | Clinical course before and after allogeneic Hematological Stem Cell Transplantation: a.** Antiretroviral treatment and chemotherapy/ immunosuppression associated with allogeneic HSCT along with plasma viral load (HIV-1 RNA) and CD4 count over time. Small numbers below blue data points indicate results of ultra sensitive viral load assay. **b.** HIV-1 DNA in PBMC and donor chimerism in T cell fraction **c.** Genotyping of CCR5 alleles with agarose gel electrophoresis of PCR amplified DNA fragments using a 100 base pair DNA ladder; NC negative control. **d.** tSNE plots of PBMC pre and post HSCT showing CCR5 expression changes and cell population changes over time. Abbreviations: HSCT: haematopoietic stem cell transplantation LACE: lomustine Ara-C cyclophosphamide etoposide; MTX methotrexate; CsA ciclosporin A; ART antiretroviral therapy; RPV rilpivirine; DTG dolutegravir; 3TC lamivudine; RAL raltegravir; TDF tenofovir disoproxil fumarate; FTC emtricitabine. These experiments were carried out once only (a-d) and sample size is  $n=1$  for all panels.



**Fig. 2 | Susceptibility of index patient CD4 T cells to CCR5 tropic and CXCR4 tropic HIV-1 and coreceptor usage by index patient viruses prior to HSCT.** **a.** Representative plots of intracellular p24 gag staining within CD4<sup>+</sup> T cell populations three days post infection of isolated CD4<sup>+</sup> cells by CCR5 (R5) tropic viruses Bal and ZM247 and CXCR4 (X4) tropic virus NL4.3 **b.** Percentage infection in CD3<sup>+</sup> CD4<sup>+</sup> T cells determined by p24 staining at day 3 and day 7 post infection using R5 and X4 tropic viruses. Error bars represent standard error of the mean. Data are representative of 3 independent experiments each conducted in duplicate. **c.** Maximum likelihood phylogenetic tree showing single genome *env* C2-V5 sequences (HXB2 *env* 367-1533 nt) from PBMC prior to HSCT. NL4.3, Ba-L and two subtype D sequences from Genbank were also used. Red nodes indicate >70% bootstrap support. Gp120 amplicons from sequences marked with an asterisk were cloned into a clade B gp160 Env plasmid. Virus *env* sequences marked by a red asterisk generated infectious virus particles when co-transfected into HEK293T cells with the envelope deficient full-length HIV plasmid encoding luciferase (NL4-3 delta Env Luc). Black asterisk indicates a sequence that did not generate infectious virus. **d.** Pseudoviruses from **c.** were used to infect U87 cells expressing either CXCR4 (X4) or CCR5 (R5). A dual tropic pseudovirus (WEAU-d15.410.787) was produced in parallel as a positive control for infection (red line). Experiments in **a**, **b**, **c** and **d.** were performed independently three times with similar results (sample size  $n=1$  healthy control donor and  $n=1$  index patient for **a** and **b**; sample size  $n=9$  clones tested in **d.**).



**Fig. 3 | HIV Specific Antibodies.** Humoral response dynamics were tested at days +26, +423, +811 and +965 after HSCT (last two time points in absence of ART). Antibody levels were measured using Western blot (a), the standard HIV-1 VITROS assay (b), a detuned low sensitive (LS) version of the HIV-1 VITROS assay (c), and the Limiting Antigen avidity assay (d). Open symbols represent values under the limit of detection. AI: Avidity Index; S/CO: Ratio signal/cut off; Allo-HSCT: allogeneic hematopoietic stem cell transplantation; ART: antiretroviral therapy. a, c, d were repeated twice independently with similar results.



## METHODS

**Patient consent pathway.** Following the clinical decision in 2015 to undertake allogeneic HSCT for treatment of aggressive lymphoma, the possibility of a CCR5 delta 32/delta 32 match was discussed with the patient. International registry searches identified no fully matched (10/10) donors. The only available donors on the international registries were the selected 9/10, and two 8/10. The 9/10 donor selected was therefore the best available match, and subsequent testing confirmed that the potential donor was also homozygous for CCR5 d32. Ultimately because the best available donor happened to be CCR5 negative, there were no deviations from the standard hospital consent protocol for HSCT, and therefore standard written informed consent for 'LACE conditioned allogeneic stem cell transplant' was obtained from the patient.

In Dec 2015, six months before HSCT, co-receptor usage was inferred from sequencing of genomic DNA that reported CCR5 tropic virus. The potential for remission was then discussed with the patient and that a supervised treatment interruption would be needed to demonstrate successful remission. Ethical approval for treatment interruption, frequent HIV viral load monitoring and tissue sampling was sought using the standard NHS framework in mid-late 2016. The protocol specified that at 12 months post-transplant, if viral load was consistently < 50 copies/ml on treatment with 'target not detected' for at least 6 months on the 2 most recent consecutive visits ART would be withdrawn and thereafter viral load would be monitored weekly for the first 3 months, monthly for a further 9 months if undetectable at all time points and three monthly between years 1 and 4. The protocol specified that if assays for the HIV reservoir were deemed negative by a group of UK experts from CHERUB we would thereafter monitor viral load 6 monthly. The protocol stated that if viral rebound occurs then moderate or severe symptoms would not be expected due to the likely low viral load where the donor chimerism is close to 100%. For the assessment of and management of risk the protocol stated that there is a risk of rebound viremia and symptoms such as fever and other flu like symptoms and that this would be mitigated by performing regular viral load testing in order to detect viral rebound early, re-starting ART where we observe at least 2 viral loads above 200 copies/ml one week apart in the absence of any other cause of viral blips, and monitoring CD4 cells (%) at least monthly for the first year. UK NHS Health Research Authority Research Ethics Committee approval was obtained in April 2017 UK with the reference number 17/SW/0021, protocol number 16/0594, and the patient provided full written, informed consent in July 2017. The interruption did not occur until Sept 2017, 16 months after transplantation. The patient was registered to the IciStem consortium as IciStem#36.

**Chimerism testing.** We measured whole leukocyte and also T-cell specific (CD3 selected) chimerism by short tandem repeats (STR) analysis with the PowerPlex 16 system.

**Primary cell culture and CD4 isolation.** Peripheral blood mononuclear cells were isolated from whole blood by centrifugation on Lymphoprep (Axis-Shield UK, UK) gradient. The cells collected at the interface were washed with PBS and stimulated for 3 days in the presence of PHA and IL-2 (at 10pg/ml) in RPMI 1640 supplemented with 10% FCS. Stimulated PBMC were used for CD4+ negative selection with antibody-coated magnetic beads (Biolegend, Mojosort UK).

**Extracellular receptor staining.** Stimulated PBMC were washed with FACS buffer (PBS + 1% FCS) then stained with viability dye (Ghost Dye Violet 450, Tonbo Bioscience), followed by anti CD3-APC, anti CD4-FITC and anti CD195-PE (CCR5) (BioLegend, UK). Cells were washed and fixed in 2% PFA (paraformaldehyde). At least 10<sup>5</sup> lymphocytes were acquired on a BD LSRFortessa flow cytometer and analyzed using FlowJo (Tree Star Inc).

**Spreading infection.** Infection of primary cells using full-length CCR5- and CXCR4-tropic HIV-1 viruses. CXCR-4 tropic hybrid clone NL4-3 and CCR5 tropic viruses Bal and ZM247 were used to infect CD4+ T-cells for 4h (623, 1150 and 430pg per well respectively), before cells were washed twice and incubated in culture medium RPMI 1640 supplemented with 10% FCS and IL-2 (at 10pg/ml) for a period of 7 days. Culture medium was changed on day 3 and the collected supernatants were stored for analysis. Cells were stained with viability dye (Ghost Dye Violet 450, Tonbo Bioscience) then fixed in 4% PFA, permeabilized (BD Perm/Wash™, BD Biosciences) and stained for intracellular p24 using anti-p24 KC57-RD1 conjugated antibody (Beckman Coulter, USA). The percentage of infected cells was monitored by flow cytometry using BD LSRFortessa flow cytometer (BD Biosciences, UK) and analyzed by FlowJo software (Tree Star, OR, USA). ZM247<sup>1</sup> was a gift from Beatrice Hahn.

**Supernatant infectivity assay on HeLa TZM-bl reporter cells.** In this assay, infectivity is measured as Tat-induced firefly luciferase reporter gene expression after a single round of virus infection. Briefly, 10<sup>4</sup> TZM-bl cells/well are seeded in a 96 well white plate in culture medium DMEM supplemented with 10% FCS for 24 h. After this, medium was replaced with supernatant collected from the infection assay at a final dilution of 1/3 and 1/6. After 48 h incubation cells were lysed by addition of Steady-Glo luciferase reagent (Promega, UK) and luminescence read using a GloMax 96 Luminometer (Promega, UK). For analysis, the relative luminescence

units (RLU) are determined following the subtraction of background luciferase activity from cell control wells (average of eight replicates) and subtraction of RLU from uninfected supernatant wells (average of 6 replicates).

**Next generation sequencing of HIV-1 Env V3 from genomic DNA.** Nested polymerase chain reaction (PCR) was performed on the isolated DNA to amplify the HIV-1 *env* region (Symons et al, Clinical Microbiology and Infection, 2011). Subsequently, PCR products were cleaned using the QiaQuick PCR purification kit (Qiagen) and amplicons were sequenced using the MiSeq v2 reagent kit (500 cycles) to yield paired-end reads of 250 bases each. Co-receptor tropism could be predicted by aligning reads to the consensus B sequence and isolating and trimming reads that overlap the entire V3 region. Unique V3 sequences that are supported by 1.75% were used for HIV-1 co-receptor tropism predicted using geno2pheno and PSSM algorithms.

**Single genome sequencing from PBMC pre HSCT.** Single genomes were generated as follows. Genomic DNA was extracted from total peripheral PBMC using the Qiagen DNAeasy kit. Two rounds of nested PCR were then performed using previously validated primers and Invitrogen High Fidelity platinum taq polymerase. 2kb *Env* amplicons were visualised by agarose gel electrophoresis and sanger sequenced using a primer internal to *Env*.

**Sequence alignment and phylogenetic tree construction.** *Env* amplicons generated by SGS were Sanger-sequenced. Prior to alignment sequences were trimmed at the 5' and 3' ends until base calls consistently reached a quality score ≥30, resulting in 99.9% accuracy of base call. Patient *env* nucleotide sequences were aligned at the protein sequence level using MUSCLE v3.8.31 (1) and mapped back to nucleotide, with minor manual adjustments. Sequences from laboratory isolates NL4.3 and Bal were included for reference, together with two HIV-1 subtype D reference isolates from the Los Alamos HIV Sequence Database (<http://www.hiv.lanl.gov/>) to serve as an outgroup. A maximum likelihood (ML) phylogeny was estimated using RAXML 8 (<https://raxml-ng.vital-it.ch/#/>), with the general time-reversible nucleotide substitution model and gamma-distributed rate heterogeneity. Stationary frequencies of nucleotides were estimated from their counts in the sequences. Clade support was estimated from 1000 non-parametric bootstrap replicate datasets. The ML phylogeny was rooted on the outgroup branch and visualised using FigTree v1.4.4 (<http://tree.bio.ed.ac.uk/software/figtree/>).

**Phenotypic determination of CCR5 or CXCR4 usage by patient-derived Env clones.** Selected amplicons were cloned into an expression vector deleted for *env* and co-transfected into HEK293T cells with the envelope deficient full length HIV plasmid encoding luciferase (NL4-3 delta Env Luc). Pseudoviruses were harvested, filtered and titrated 3-fold in U87 cells expressing either CXCR4 (X4) or CCR5 (R5). A dual tropic pseudovirus (WEAU-d15.410.787) was produced in parallel as a positive control for infection. After 48 h incubation cells were lysed by addition of Steady-Glo luciferase reagent (Promega, UK) and luminescence read using a GloMax 96 Luminometer (Promega, UK).

**Modified Quantitative Viral Outgrowth Assay (QVOA).** Virus outgrowth assay was performed as previously described with modifications. Briefly, total CD4+ T cells were isolated from PBMCs by immune-magnetic negative selection (StemCell Technologies). Cells displaying activation markers (CD25/ CD69 / HLA-DR) were labelled with FITC-conjugated antibodies (Biolegend) and depleted by FITC selection kit (StemCell Technologies). T cells with activation markers adhering to the beads were recovered, additionally activated with phytohemagglutinin-L (PHA-L, Sigma), seeded in a limiting dilution and co-cultured with SupT1-CCR5 for at least 21 days.

Resting CD4+ T cells were recovered from the eluant and cultured in the presence of 100nM raltegravir and 20nM efavirenz for 1-3 days to allow unintegrated viral DNA to degrade. After which resting CD4+ T cells were counted, activated with PHA-L, 10 fold excess of irradiated allogeneic PBMC and 10 units/ml interleukin-2 (IL-2, NIBSC) and seeded in a limiting dilution. The activation mix was washed away 24h later and SupT1-CCR5 cells were added to each co-culture well.

The dilution series include replicates at 2.5million, 0.5million and 0.1 million CD4+ T cells per well as appropriate. Co-cultures were maintained for at least 21 days. Cells were monitored for syncytia formation, and the supernatant was sampled regularly for p24. The infectious unit per million cells were calculated by limiting dilution statistics.

**Reagents for QVOA.** Interleukin-2 (NIBSC repository reference ARP901) was obtained from the Centre for AIDS reagents, National Institute of Biological Standards and Control (NIBSC), United Kingdom. Raltegravir was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Raltegravir (Cat # 11680) from Merck & Company, Inc. Efavirenz was also obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Efavirenz.

**Residual viremia by single copy assay / ultra sensitive VL (usVL).** Residual viremia (HIV-RNA) was measured by ultracentrifugation of up to 6.5 ml of plasma (4-6.5ml) at 43100 rpm at 4°C for 30 minutes, followed by viral RNA extraction using the m2000sp Abbot RealTime HIV-1 Assay device and laboratory-defined

applications software from the instrument. HIV-1 RNA copies in the low range were determined by an in-house calibration curve set (range,  $10\text{-}10^3$  absolute copies), which had previously been validated using a standard HIV-1 DNA control from the WHO in the range of 128–0.5 copies/mL. Limit of detection was calculated relative to the plasma volume used in each sample.

**Quantification of HIV Antibodies.** Specific HIV-1 antibodies in longitudinal sera samples were tested in a qualitative western blot assay (New Lav Blot I, Bio-Rad). Standard and low sensitive (LS) versions of the Vitros anti-HIV-1 assay (Ortho-Clinical Diagnostics) as well as the limiting avidity antigen assay were also measured in same samples as previously described<sup>2</sup>. Briefly, four recombinant antigens (HIV-1 Env 13, HIV-1 Env 10, HIV-1 p24, and HIV-2 Env AL) derived from HIV-1 core, HIV-1 envelope, and HIV-2 envelope proteins were quantified. The optimized version of the LS-Vitros assay (detuned or LS version) uses a 1:400 dilution of HIV-positive sample. The cut off was set up at 20 S/CO. The avidity assay measures the capacity of the guanidine to elute low-avidity and low-affinity antibodies after antigen-antibody bonds have formed. The results are reported as an avidity index (AI), which was calculated as a ratio of the S/CO of the sample incubated in guanidine to the S/CO of the sample incubated in PBS. Cut off was established at 0.51.

**Flow Cytometry.** The following fluorochrome-conjugated antibodies were used in this study: CD14 BV510, CD19 BV510, CD3 APC Fire 750 or CD3 BV605, CD4 PE/Dazzle 594, or CD4 APC Fire 750, CD8 BV421, CCR5 PE/Dazzle 594, CD56 PeCy7 (Biolegend) for surface antigens; and IFN- $\gamma$  PeCy7, TNF- $\alpha$  FITC (Biolegend) and IL-2 PercP eFluor710 (eBioscience), for intracellular staining. PBMC were washed in PBS, and surface stained at 4°C for 20 min with saturating concentrations of

different combinations of antibodies in the presence of fixable live/dead stain (Invitrogen). Cells were then fixed and permeabilized for detection of intracellular antigens. Cells were acquired on a BD Fortessa X20 using BD FACSDiva8.0 (BD Bioscience) and analysed using FlowJo 10 (Tree Star). Stochastic neighbor embedding (SNE) analysis was performed using the mrc.cytobank platform.


**Intracellular cytokine staining.** PBMCs were thawed and resuspended in RPMI complete media. Following, overnight rest at 37°C and 5%CO<sub>2</sub>, PBMCs were stimulated for 6 hours with 2 $\mu$ g/ml HIV-1 Gag pools or CMV pp65 (JPT Peptide Technologies) in the presence of 1 $\mu$ g/mL anti-CD28 and anti-CD49d CoStim<sup>tm</sup> antibodies (BD Biosciences), 2  $\mu$ M Monensin (BD biosciences), 10  $\mu$ g/mL Brefeldin A (Sigma) and anti-CD107a BV605 (Biolegend). Where indicated and cell numbers permitted PMBCs were stimulated with 2 $\mu$ g/ml HIV-1 Env, Pol and Nef peptide pools. Following stimulation virus specific T cells were identified via intracellular cytokine staining (ICS) as previously described. In brief, cells were surface, fixed and permeabilised (CytoFix/CytoPerm<sup>TM</sup> BD Biosciences) followed by ICS for IFN- $\gamma$  PeCy7, TNF- $\alpha$  FITC, and IL-2 PercP eFluor710 (eBioscience). Stimulation with 0.005% DMSO in the presence of costimulatory antibodies, protein transport inhibitors and CD107a was performed as a negative control.

**Reporting summary.** Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.


### Data availability

SGA Sequences are available via GenBank under accession numbers MK493056-MK493075. The following figures have associated raw data: Figures 1, 2, 3, 4.

ACCELERATED ARTICLE PREVIEW




Extended Data Fig. 1 | Blood Cell populations over time. Abbreviations: HSCT: haematopoietic stem cell transplantation; Csa ciclosporin A; ART antiretroviral therapy; RPV rilpivirine; DTG dolutegravir; 3TC lamivudine.




CCR5 expression in CD3<sup>+</sup> CD4<sup>+</sup> cells


**b.** Index patient



Control




**c.**



**Extended Data Fig. 2 | Susceptibility of index patient CD4 T cells to R5 tropic and X4 tropic HIV-1** **a.** Experimental flow for measurement of infection by intracellular p24 gag staining. Control cells were from a healthy HIV-CCR5<sup>+</sup> donor. **b.** Flow cytometry analysis of PBMC following 3 days of stimulation exhibiting the expression pattern of CCR5 receptor within CD3<sup>+</sup> CD4<sup>+</sup> T cells in both healthy donor (control) and

index patient. **c.** Culture supernatants from CD4 T cells infected with R5 and X4 tropic viruses were collected on days 3 and 7 to measure infectivity on HeLa TZM-bl reporter cells. Infectivity is measured as a reduction in Tat-induced firefly luciferase reporter gene expression in TZM-bl. Error bars represent standard error of the mean. N=2: one donor and one index patient. Experiments were repeated 3 times with similar results.



**Extended Data Fig. 3 | CD8+ T cell responses and CD4 T cell responses to HIV.** Representative FACS plots showing percentage of virus specific CD8+ T cells (top panel) and CD4+ T cells (bottom panel) identified via

intracellular staining for IFN-g, following stimulation with HIV Pol, Env and Nef peptide pools post-HSCT at days +D96 and +D819.

Extended Data Table 1 | Comparison of blood group and tissue typing between stem cell donor and index case

	Donor	Recipient
Blood group (Rhesus)	A(+)	A(+)
CMV Status	+	+
HLA-A	11:01,24:02	11:01,24:02
HLA-B	14:02, <b>51:01</b>	14:02, <b>51:07</b>
HLA-Cw	08:02,14:02	08:02,14:02
HLA-DR	01:02,13:01	01:02,13:01
HLA-DQ	05:01,06:03	05:01,06:03

ACCELERATED ARTICLE PREVIEW

Extended Data Table 2 | Detection of bands on western blot pre- and post- transplantation

Days post allo-HSCT	Observed Bands	Bands left
26	GP160, GP110/120, GP41, p68, p55, p52, p40, p31, p24, p18	None
423	GP160, <b>GP110/120 faint</b> , GP41, <b>p31 faint</b> , <b>p24 very faint</b>	p68, p55, p52, p40, p18
811	GP160, <b>GP110/120 faint</b> , GP41, <b>p31 very faint</b>	p68, p55, p52, p40, p24, p18
965	GP160, <b>GP110/120 very faint</b> , GP41, p18	p68, p55, p52, p40, p24, p31

ACCELERATED ARTICLE PREVIEW

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR state that no software was used.

Data analysis

Graph Pad Prism 8  
<http://silicianolab.johnshopkins.edu/> for calculation of IUPM

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Sequences have been submitted to Genbank: MK493056-MK493075

Figures with raw data: Fig 1, 2, 3, 4

There are no restrictions on data availability

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	n=1, case report
Data exclusions	no exclusions
Replication	we did technical as well as biological replicates in experiments involving patient derived cells or plasma
Randomization	NA
Blinding	There was no blinding

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involvement in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data

### Methods

n/a	Involvement in the study
<input type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	The following fluorochrome-conjugated antibodies were used in this study: CD14 BV510, CD19 BV510, CD3 APC Fire 750 or CD3 BV605, CD4 PE/Dazzle 594, or CD4 APC Fire 750, CD8 BV421, CCR5 PE/Dazzle 594, CD56 PeCy7 (Biolegend) for surface antigens; and IFN- PeCy7, TNF- FITC (Biolegend) and IL-2 PercP eFluor710 (eBioscience)
Validation	These antibodies have all been validated in previous publications

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	TZMBL from NIH AIDS Reagent repository; HEK 293T cells. U87 CD4+CCR5+ Cells (Catalog Number 4035) and U87 CD4+CCR5+ Cells (Catalog Number 4036) were obtained from the NIH AIDS reagents program. 293T/17 [HEK 293T/17] cells for pseudovirus production were obtained from ATCC (CRL-11268).
Authentication	none of the cell lines used were authenticated
Mycoplasma contamination	Cell lines were tested negative for mycoplasma
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	The ATCC stock of the parental cell line U87 MG has been shown to be different to the original U87 stock generated at the University of Uppsala Sweden. The U87 cells used in this study were derived from the original Swedish line not the ATCC line as documented by the NIH AIDS reagents program. These are the gold standard cells for determining co-receptor use of HIV viruses.

## Palaeontology

Specimen provenance *Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).*

Specimen deposition *Indicate where the specimens have been deposited to permit free access by other researchers.*

Dating methods *If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.*

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals *For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.*

Wild animals *Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.*

Field-collected samples *For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.*

Ethics oversight *Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics individuals who are HIV infected undergoing HSCT with delta 32 homozygous donor tissue

Recruitment This is extremely rare and is a case report that had full ethical approval for analytical treatment interruption

Ethics oversight Ethical approval for this study 'HIV treatment interruption following Stem cell transplantation with CCR5 negative donor cells for haematological malignancy' was obtained from the UK Health Research Authority Research Ethics Committee reference number 17/SW/0021, protocol number 16/0594. Written informed consent was obtained from the individual.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration NA - it is not a trial

Study protocol available from authors

Data collection from Dec 2015 to Feb 2019

Outcomes time to viral rebound, reservoir size by QVOA, PCR on CD4 T cells, CD4 trends, cancer remission

## ChIP-seq

### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links *For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, May remain private before publication. provide a link to the deposited data.*

Files in database submission

*Provide a list of all files available in the database submission.*Genome browser session  
(e.g. [UCSC](#))*Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.*

## Methodology

Replicates

*Describe the experimental replicates, specifying number, type and replicate agreement.*

Sequencing depth

*Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.*

Antibodies

*Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.*

Peak calling parameters

*Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.*

Data quality

*Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.*

Software

*Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.*

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

PBMC were washed in PBS, and surface stained at 4°C for 20 min with saturating concentrations of different combinations of antibodies in the presence of fixable live/dead stain (Invitrogen). Cells were then fixed and permeabilized for detection of intracellular antigens

Instrument

Fortessa X20 using BD FACSDiva8.0 (BD Bioscience)

Software

FloJo

Cell population abundance

see supplementaries

Gating strategy

see supplementaries

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type

*Indicate task or resting state; event-related or block design.*

Design specifications

*Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.*

Behavioral performance measures

*State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).*

## Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI  Used  Not used

## Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

## Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis:  Whole brain  ROI-based  Both

Statistic type for inference (See [Eklund et al. 2016](#))

Correction

## Models & analysis

n/a | Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis